A rare case of transthyretine amyloidosis with heart damage and widespread systemic manifestations


如何引用文章

全文:

详细

The article describes the rare clinical case of transthyretine amyloidosis in young patient, manifested by heart rhythm disturbances and biventricular heart failure.

作者简介

S. Boldueva

I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation

Email: svetlanaboldueva@mail.ru
д-р мед. наук, проф., зав. каф. факультетской терапии 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41

M. Samokhvalova

I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation

канд. мед. наук, зав. кардиологическим отд-нием клиник 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41

A. Khomulo

I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation

врач-кардиолог кардиологического отд-ния клиник 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41

V. Zaitsev

V.A.Almazov National Medical Research Center of the Ministry of Health of the Russian Federation

врач-кардиолог главного клинического комплекса 197341, Russian Federation, Saint Petersburg, ul. Akkuratova, d. 2

V. Marinin

I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation

зав. аритмологическим отд-нием клиник 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41

S. Vinnichuk

I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation

зав. патологоанатомическим отд-нием клиники, канд. мед. наук, доц. каф. патологической анатомии 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41

参考

  1. Шилов Е.М. Нефрология. 2-е изд., испр. и доп. М.: ГЭОТАР-Медиа, 2010; с. 352-70
  2. Лутай М.И. и др. Амилоидоз сердца: трудный диагноз. Здоровая Украина. 2012; с. 34-7
  3. Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis. J Am Coll Cardiol 2015; 66 (21): 2451-66.
  4. Болдуева С.А., Самохвалова М.В., Богданова Е.В., Соловьева Т.C. Первичный системный амилоидоз с поражением сердца и коронарных артерий. Кардиология. 2010; 6: 92-4
  5. Connors L.H, Prokaeva T, Lim A.et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 2009; 158: 607-14.
  6. Ng B, Connors L.H, Davidoff R. et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165: 1425-9.
  7. Ruberg F.L, Maurer M.S, Judge D.P et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J 2012; 164: 222-8.e1.
  8. Sekijima Y, Uchiyama S, Tojo K. et al. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol 2011;42: 1785-91.
  9. Ackermann E.J, Guo S, Booten S. et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 2012; 19 (Suppl. 1): 43-4.
  10. Maurer M.S, Grogan D.R, Judge D.P et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail 2015; 8: 519-26.
  11. Obici L, Cortese A, Lozza A. et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 2012; 19 (Suppl. 1): 34-6.
  12. Wu S.Y, Lopez-Berestein G, Calin G.A et al. RNAi therapies: drugging the undruggable. Sci Transl Med 2014; 6: 240ps7.
  13. Benson M.D. Liver transplantation and transthyretin amyloidosis. Muscle Nerve 2013; 47: 157-62.
  14. Carvalho A, Rocha A, Lobato L. Liver transplantation in transthyretin amyloidosis: issues and challenges. Liver Transpl 2015; 21: 282-92.
  15. Ericzon B.G, Wilczek H.E, Larsson M et al. Liver Transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 2015;99: 1847-54.
  16. Maia L.F, Magalhes R, Freitas J et al. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J Neurol Neurosurg Psychiatry 2015;86: 159-67.
  17. Oshima T, Kawahara S, Ueda M. et al. Changes in pathological and biochemical findings of systemic tissue sites in familial amyloid polyneuropathy more than 10 years after liver transplantation. J Neurol Neurosurg Psychiatry 2014; 85: 740-6.

版权所有 © Eco-Vector, 2017

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。

##common.cookie##